CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Lifestyle Modifications for Preventing and Treating Heart Failure From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Clinical Trial21 (12), 1596-1604

JOURNAL:Eur J Heart Fail. Article Link

Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Trial

B Pieske, MJ Patel, VICTORIA Study Group et al. Keywords: cyclic guanosine monophosphate; HFrEF; soluble guanylate cyclase

FULL TEXT PDF